Dyne Therapeutics Appoints New CEO, Dr. Kristin Yarema
Ticker: DYN · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.0001, $700,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, personnel
Related Tickers: EDIT
TL;DR
Dyne Therapeutics just hired Dr. Kristin Yarema as CEO, replacing Joshua Brumm.
AI Summary
Dyne Therapeutics, Inc. announced on March 21, 2024, the appointment of Dr. Kristin Yarema as Chief Executive Officer and a member of the Board of Directors, effective immediately. Dr. Yarema previously served as President and CEO of Editas Medicine. The company also announced the departure of its former CEO, Joshua Brumm, and the appointment of Dr. Yarema as interim CEO on March 15, 2024.
Why It Matters
The appointment of a new CEO can signal a strategic shift or renewed focus for the company, potentially impacting its future development and stock performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Registrant
- Dr. Kristin Yarema (person) — Newly appointed CEO and Board Member
- Joshua Brumm (person) — Departing CEO
- Editas Medicine (company) — Dr. Yarema's previous employer
- March 21, 2024 (date) — Effective date of appointment
- March 15, 2024 (date) — Date Dr. Yarema was appointed interim CEO
FAQ
Who has been appointed as the new CEO of Dyne Therapeutics?
Dr. Kristin Yarema has been appointed as the new Chief Executive Officer of Dyne Therapeutics.
When is Dr. Kristin Yarema's appointment effective?
Dr. Kristin Yarema's appointment is effective immediately as of March 21, 2024.
Who did Dr. Kristin Yarema replace as CEO?
Dr. Kristin Yarema replaces Joshua Brumm as CEO.
What was Dr. Yarema's previous role?
Dr. Yarema previously served as President and CEO of Editas Medicine.
When was Joshua Brumm's departure officially noted?
The filing notes the departure of Joshua Brumm, with Dr. Yarema having been appointed interim CEO on March 15, 2024.
Filing Stats: 2,429 words · 10 min read · ~8 pages · Grade level 10.9 · Accepted 2024-03-25 07:39:54
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
- $700,000 — ll be paid an annualized base salary of $700,000 and will be eligible to receive an annu
Filing Documents
- d93072d8k.htm (8-K) — 40KB
- d93072dex101.htm (EX-10.1) — 77KB
- d93072dex103.htm (EX-10.3) — 80KB
- d93072dex104.htm (EX-10.4) — 38KB
- d93072dex105.htm (EX-10.5) — 59KB
- g93072g0322194520636.jpg (GRAPHIC) — 5KB
- g93072gdsp19.jpg (GRAPHIC) — 8KB
- 0001193125-24-075932.txt ( ) — 517KB
- dyn-20240321.xsd (EX-101.SCH) — 3KB
- dyn-20240321_lab.xml (EX-101.LAB) — 18KB
- dyn-20240321_pre.xml (EX-101.PRE) — 11KB
- d93072d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: March 25, 2024 By: /s/ John Cox Name: John Cox Title: President and Chief Executive Officer